Osteoarthritis Companies | Market Research Future

Top Industry Leaders in the Osteoarthritis Market

Latest Osteoarthritis Companies Update

November 2023: For the treatment of pain and inflammation associated with soft tissue surgery and chronic osteoarthritis (OA) in canines, Krka introduced Robexera, the first generic robenacoxib solution. Anti-inflammatory pain relief is provided by the once-daily administration regimen of Robexera, a COX2-NSAID formulation. To assist pet caretakers in administration, the product is presented as a flavored chewable tablet. A set of perforated blisters, four strengths of PIL sheets that convert to prescribing envelopes, and color-coded cases are included in each pack to facilitate dispensing. With its bioequivalence to the originator product, Robexera offers veterinary practices and their clients improved affordability and targeted pain relief. This is especially beneficial for clients whose animals are undergoing long-term pain management programs or have other health conditions, as it further enhances the value proposition for these practices.

July 2023: Swiss pharmaceutical company Sandoz announced the launch of a biosimilar version of the drug. Aside from offering an unbranded version of Humira at an 81% discount, the Novartis-owned company stated that its medication, Hyrimoz, would be priced at a 5% reduction from Humira's current published price of $6,922 per month. As a means of attracting pharmacy benefit managers, which base a portion of their revenue on the discounts they negotiate on behalf of their clients—large employers and health insurance plans—drug manufacturers will likely introduce Humira biosimilars with modest discounts, according to healthcare experts. As opposed to pharmacy benefit managers, which typically do not pursue after-market discounts, healthcare systems that function as both providers and insurers may be drawn to the more affordable variant.

List of Osteoarthritis Key companies in the market